EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access

Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Amir Goldkorn, Catherine Tangen, Melissa Plets, Daniel Bsteh, Tong Xu, Jacek K Pinski, Sue Ingles, Timothy Junius Triche, Gary R MacVicar, Daniel A Vaena, Anthony W Crispino, David James McConkey und 7 weitere

JAMA Network Open · 07.10.2024 · 7 (10) · e2437871

DOI: 10.1001/jamanetworkopen.2024.37871 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 07.10.2024. Verfasst von Amir Goldkorn und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, Keck School of Medicine of USC, Los Angeles, California. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance In metastatic hormone-sensitive prostate cancer (mHSPC), new first-line combination therapies have enhanced overall survival (OS), but clinical outcomes for individual patients vary greatly and are difficult to predict. Peripheral blood circulating tumor cell (CTC) count is the most extensively validated prognostic liquid biomarker in metastatic castration-resistant prostate cancer (mCRPC), and recent studies have suggested that it may also be informative in mHSPC.

Objective

To examine the prognostic value of CTC count in men with mHSPC. Design, Setting, and Participants In this prognostic study, peripheral blood was drawn at registration (baseline) and at progression to mCRPC in the S1216 study (March 1, 2013, to July 15, 2017), a phase 3, prospective, randomized clinical trial in men with mHSPC. The CTCs were enumerated using a US Food and Drug Administration–cleared isolation platform. Counts were categorized as 0, 1 to 4, or 5 or more CTCs per 7.5 mL based on the prognostic value of these cut points in prior studies. The data analysis was performed between October 28, 2022, and June 15, 2023. Exposure Metastatic hormone-sensitive prostate cancer. Main Outcomes and Measures Circulating tumor cell count was evaluated for an association with 3 prespecified trial end points: OS, progression-free survival, and 7-month prostate-specific antigen, after adjusting for other baseline covariates using proportional hazards and logistic regression models.

Results

Of 1313 S1216 participants (median [IQR] age, 68 [44-92] years), evaluable samples from 503 (median [IQR] age, 69 [46-90] years) with newly diagnosed mHSPC were collected at baseline, and 93 samples were collected at progression. Baseline counts were 5 or more CTCs per 7.5 mL in 60 samples (11.9%), 1 to 4 CTCs per 7.5 mL in 107 samples (21.3%), and 0 CTCs per 7.5 mL in 336 samples (66.8%). Median OS for men with 5 or more CTCs per 7.5 mL was 27.9 months (95% CI, 24.1-31.2 months) compared with 56.2 months (95% CI, 45.7-69.8 months) for men with 1 to 4 CTCs per 7.5 mL and not reached at 78.0 months follow-up for men with 0 CTCs per 7.5 mL. After adjusting for baseline clinical covariates, men with 5 or more CTCs per 7.5 mL at baseline had a significantly higher hazard of death (hazard ratio, 3.22; 95% CI, 2.22-4.68) and disease progression (hazard ratio, 2.46; 95% CI, 1.76-3.43) and a lower likelihood of prostate-specific antigen complete response (odds ratio, 0.26; 95% CI, 0.12-0.54) compared with men with 0 CTCs per 7.5 mL at baseline. Adding baseline CTC count to other known prognostic factors (covariates only: area under the curve, 0.73; 95% CI, 0.67-0.79) resulted in an increased prognostic value for 3-year survival (area under the curve, 0.79; 95% CI, 0.73-0.84). Conclusions and Relevance In this prognostic study, the findings validate CTC count as a prognostic biomarker that improved upon existing prognostic factors and estimated vastly divergent survival outcomes regardless of subsequent lines of therapy. As such, baseline CTC count in mHSPC may serve as a valuable noninvasive biomarker to identify men likely to have poor survival who may benefit from clinical trials of intensified or novel regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplastic Cells, CirculatingMaleHumansAgedPrognosisMiddle AgedProspective StudiesProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantAged, 80 and overBiomarkers, TumorNeoplasm MetastasisProstate-Specific Antigen

Substanzen

Biomarkers, TumorProstate-Specific Antigen

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Medicine, Keck School of Medicine of USC, Los Angeles, California.
  • USC Norris Comprehensive Cancer Center, Los Angeles, California.
  • SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, Washington.
  • Keck School of Medicine of USC, Los Angeles, California.
  • Children's Hospital Los Angeles, University of Southern California, Los Angeles.
  • Illinois CancerCare PC, Peoria.

Förderung

  • NCI NIH HHS

Zitieren

APA

Goldkorn, A., Tangen, C., Plets, M., Bsteh, D., Xu, T., Pinski, J. K., Ingles, S., Triche, T. J., MacVicar, G. R., Vaena, D. A., Crispino, A. W., McConkey, D. J., Lara, P. N., Hussain, M. H. A., Quinn, D. I., Dorff, T. B., Lerner, S. P., Thompson, I., & Agarwal, N. (2024). Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer. JAMA Network Open, 7(10), e2437871. https://doi.org/10.1001/jamanetworkopen.2024.37871

Vancouver

Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski JK, et al. Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer. JAMA Network Open. 2024;7(10):e2437871. doi:10.1001/jamanetworkopen.2024.37871

BibTeX
@article{Goldkorn2024,
  author = {Goldkorn, Amir and Tangen, Catherine and Plets, Melissa and Bsteh, Daniel and Xu, Tong and Pinski, Jacek K and Ingles, Sue and Triche, Timothy Junius and MacVicar, Gary R and Vaena, Daniel A and Crispino, Anthony W and McConkey, David James and Lara, Primo N and Hussain, Maha H A and Quinn, David I and Dorff, Tanya B and Lerner, Seth Paul and Thompson, Ian and Agarwal, Neeraj},
  title = {Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {10},
  pages = {e2437871},
  doi = {10.1001/jamanetworkopen.2024.37871}
}
Kostenlos starten →